Laura E. Niklason

All filings by Laura E. Niklason on record concern Humacyte, Inc., in the capacity of chief executive. Between 26 August 2021 and 20 August 2025, the trades on record add up to 46 filings.

Market trades split into 8 purchases (€13.1M) and 34 sales (€70.1M). The net balance comes to €57.0M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants and 2 option exercises. So far in 2025, the count stands at no purchases and 3 sales.

A typical purchase (the median) is worth €14k. Of 7 purchases, 7 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 20 August 2025, the filings show an open-market sale worth €1.5M in Humacyte, Inc. The clock since the last published purchase (21 November 2024) now reads 702 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.